Previous phase | Next Phase
Preparing for a successful launch
The majority of drugs that enter Phase III end up getting approved by the FDA. While final approval might still be some time away, the near-certainty of approval warrants manufacturers at Phase III to begin completing the legwork needed to bring a drug to the market. On top of additional Market Access and Market Intelligence initiatives, you also need to begin the long list of Commercialization activities that need completed.
That includes beginning to develop your channel strategy, starting the state licensing process, getting your drug listed in compendia databases, and much more.
Services We Recommend
at Phase III
Commercialization
Retail Channel Strategy
and Implementation
Managing the logistics and flow of information about your new retail product is a key to being as efficient as possible with your commercialization efforts.
Learn More
Specialty Channel Strategy
and Implementation
Bringing specialty drugs to market, while increasingly common, requires properly managing your channel and the flow of data and analytics.
Learn More
Patient Services Strategy and Implementation
Ensuring that patients, healthcare providers and caregivers all have the information they need to access and properly use your treatment is important for all new drug launches.
Learn More
Learn More
Learn More
Learn More
Compendia
Many see compendia databases as just a pricebook, but they’re so much more. In fact, an incorrect classification can mean a failed launch.
Learn More
State Licensing
In many ways, timely state licensing is just as important for your launch as the FDA approval process.
Learn More
Trade Management
Missing or incorrect serialization decisions can put your launch on hold, or cause considerable increases in costs
Learn More
Learn More
Learn More
Learn More
Market Access
US and Global
Pricing Strategy
To maximize your revenue, it’s vital that you develop proper strategy that takes payers, physicians and patients into consideration.
Learn More
US and Global Market
Access Landscape
Gaining a thorough understanding of the market, as well as the future environment, is critical for sound decision making.
Learn More
Patient Out of
Pocket Analysis
It’s imperative manufacturers have a thorough understanding of out of pocket (OOP) costs and the reimbursement support options available to them.
Learn More
Learn More
Learn More
Learn More
US and Global Payer Panel and Advisory Board
To understand the pricing and market access potential for new treatments, clients need to hear from KOLs and payers. At Two Labs, we conduct blinded and unblinded panels, depending on your needs.
Learn More
Payer Segmentation, Contracting and Plan by Plan Analysis
In today’s competitive landscape, a one-size-fits-all approach to your market access strategy is not enough.
Learn More
Learn More
Learn More
Market Intelligence
Clinical Landscape &
Pipeline Analysis
Increase your awareness of your drug’s disease landscape and competitor activities to determine how to differentiate your drug in the market to be successful.
Learn More
Medical Congress
Coverage
Save time and money without losing out on important developments in the pharma world with our full medical congress coverage services.
Learn More
Qualitative Market
Research
Understand what physicians and patients want to see from your new product with our in-depth primary source interviewing services.
Learn More
Learn More
Learn More
Learn More
Commercial Organization Benchmarking
Gain the most from your benchmarking study with our key insights, complete with an action list and detailed recommendations.
Learn More
Launch
Analog
We help optimize your launch strategy by analyzing what worked and didn’t work for similar drugs so you can properly develop a successful launch strategy.
Learn More
Competitive
Simulations
Our Competitive Simulations are your key to deeper competitor insight and a smarter business development strategy.
Learn More
Learn More
Learn More
Learn More
In-Licensing and
Acquisition Support
Our extensive experience monitoring and assessing all therapeutic categories allows us to provide insights to support licensing and acquisition decisions.
Learn More
Learn More